Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Murphy on Future Research Efforts With Pazopanib Plus SBRT in Pediatric Sarcoma

April 6th 2021

Erin Murphy, MD, discusses future research efforts with pazopanib plus stereotactic body radiation therapy in patients with pediatric sarcoma.

Dr. Wagner on the Rationale for Immunotherapy in Angiosarcoma

April 5th 2021

Michael Wagner, MD, discusses the rationale for using immunotherapy in the treatment of patients with angiosarcoma.

FDA Grants Fast Track Status to Annamycin for Soft Tissue Sarcoma Lung Metastases

March 30th 2021

The FDA has granted a fast track designation for annamycin as a treatment for patients with soft tissue sarcoma lung metastases.

Dr. Trent on the Utility of ctDNA to Understand Primary Mutations in GIST

March 19th 2021

Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.

Extremity Sarcoma Trial Utilizes Patient Willingness Outcomes to Gauge Accrual

March 19th 2021

Most patients with extremity sarcoma are willing to participate in a randomized clinical trial exploring various postoperative cancer surveillance regimens.

Presence of Pathogenic Variants Provide Rationale for Germline Sequencing in Pediatric Rhabdomyosarcoma

March 3rd 2021

Pathogenic germline variants identified among children and young adults with rhabdomyosarcoma suggest that all children with RMS should undergo germline sequencing to utilize available surveillance guidelines and inform potential gene-specific therapy options.

Dr. Wagner on the Safety Profile of Nivolumab/Ipilimumab in Angiosarcoma

March 2nd 2021

Michael Wagner, MD, discusses the safety profile of nivolumab plus ipilimumab in patients with angiosarcoma.

Dr. Trent on the Need for Novel Combination Strategies in Metastatic GIST

February 24th 2021

Jonathan C. Trent, MD, PhD, discusses the need to develop novel combination strategies for the treatment of patients with metastatic gastrointestinal stromal tumors.

Next-Generation Sequencing Reveals Potentially Actionable Mutations in Sarcoma

February 18th 2021

February 18, 2021 — The use of next-generation sequencing demonstrated that 34% of patients with sarcoma had potentially actionable mutations.

Dr. Dhir on Ongoing Research Efforts in Epithelioid and Synovial Sarcoma

February 16th 2021

Aditi Dhir, MD, discusses ongoing efforts in epithelioid and synovial sarcoma.

NBTXR3 Activity in Soft Tissue Sarcoma Could Be Replicated in Other Cancers

February 15th 2021

NBTXR3, a novel radioenhancer, is showing intriguing response rates in adult patient with soft tissue sarcoma, paving a path for the innovative therapy not just in sarcomas, but other tumor types, as well.

Risk-Based Therapy for Local Control in Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcoma Shows Promise

February 11th 2021

R. Lor Randall, MD, discusses the intriguing risk-stratification–based trial in NSTRS and how the findings can be used to guide treatment decisions in this pediatric population.

Dr. Dhir on Risk-Based Stratification in Epithelioid and Synovial Sarcoma

February 10th 2021

Aditi Dhir, MD, discusses risk-based stratification in patients with epithelioid and synovial sarcoma.

Dr. Wagner on Responses Achieved With Nivolumab/Ipilimumab in Angiosarcoma

February 9th 2021

Michael Wagner, MD, discusses responses achieved with nivolumab plus ipilimumab in patients with angiosarcoma.

Dr. Dhir on Diagnostic Challenges in Sarcoma

February 5th 2021

Aditi Dhir, MD, discusses the challenges of diagnosing patients with sarcoma.

Dr. Wagner on Future Research Efforts in Sarcoma Subtypes

February 4th 2021

Michael Wagner, MD, discusses future research efforts in sarcoma subtypes.

Dr. Wagner on the Potential for Immunotherapy in Angiosarcoma

February 3rd 2021

Michael Wagner, MD, discusses the potential use of immunotherapy in patients with angiosarcoma.

Dr. Murphy on the Utility of Pazopanib Plus SBRT in Pediatric Sarcoma

January 29th 2021

Erin Murphy, MD, discusses the utility of pazopanib plus stereotactic body radiation therapy in pediatric sarcoma.

FDA Grants Orphan Drug Designation to Ilixadencel for Soft Tissue Sarcoma

January 26th 2021

January 26, 2021 - The FDA has granted the cell-based, off-the-shelf immune primer ilixadencel an orphan drug designation for use as a treatment option in patients with soft tissue sarcoma.

Bioengineered Models Could Improve Understanding of Bone Cancer, Metastases

January 26th 2021

R. Lor Randall, MD, FACS, discusses the rationale and motivation behind tissue-engineered platforms and how they could significantly impact the understanding of how cancer arises in or metastasizes to bone.